IBC-Ab002 Shows Favorable Safety Profile, Exploratory Biomarker Signals in Alzheimer Disease Trial

In recent news, an investigational anti-PD-L1 antibody dubbed IBC-Ab002 demonstrated a favorable safety and tolerability profile and target engagement in a phase 1b trial of patients with early Alzheimer disease (AD), with exploratory analyses showing reductions in select cerebrospinal fluid (CSF) biomarkers associated with neuronal and synaptic injury.

The findings, published in Nature Medicine and presented as a late-breaking study at the 2026 Alzheimer's Association International Conference (AAIC), held July 12-15 in London, provided early clinical evidence supporting further investigation of a peripheral immune-based approach to Alzheimer disease.¹

The randomized, double-blind, phase 1b IBC-01-01 trial evaluated IBC-Ab002, a short-acting, investigational anti-PD-L1 monoclonal antibody developed by ImmunoBrain Checkpoint Inc. The study was designed primarily to evaluate safety and tolerability, while also assessing target engagement and exploratory biomarker outcomes. According to the company, the findings suggest that intermittent checkpoint inhibition may influence biomarkers associated with neuronal and synaptic injury, although the study was not designed or powered to establish clinical efficacy.

"Our approach, the first of its kind, aims to restore the immune system's ability to protect and repair the brain," Michal Schwartz, PhD, scientific co-founder and chief scientific officer of ImmunoBrain Checkpoint Inc, said in a statement.² "It is rewarding to see how curiosity-driven research that challenged the long-standing dogma that the brain is isolated from the immune system has led to a paradigm shift in our understanding of neurodegenerative diseases. By targeting a common repair pathway rather than the primary cause of the disease, this work has now translated into encouraging clinical results."

Study Overview

The phase 1b trial enrolled patients with early AD across 11 centers in the United Kingdom, Israel, and the Netherlands. Participants were randomly assigned to receive different doses of IBC-Ab002 or placebo and were followed for 48 weeks.

For context, IBC-Ab002 is a fully human anti-PD-L1 monoclonal antibody designed to temporarily modulate peripheral immune activity. Unlike conventional checkpoint inhibitors used in oncology, the investigational therapy has been engineered with a short half-life and an Fc modification intended to produce intermittent rather than sustained exposure. The company's approach is based on research led by Schwartz, who is also a professor at the Weizmann Institute of Science, which has investigated the role of the peripheral immune system in supporting brain protection and repair.¹

Results

At the end of the 48-week treatment period, IBC-Ab002 demonstrated target engagement and was generally well tolerated across the evaluated dose levels, according to findings presented by the company.

Exploratory CSF biomarker analyses showed that most patients who received the highest dose demonstrated reductions across a panel of biomarkers associated with neuronal and synaptic injury. These included neurogranin, total tau, and phosphorylated tau 181 (p-tau181).

The biomarker findings are of particular interest because neurogranin has been associated with synaptic dysfunction and injury, while total tau and p-tau181 are established markers of neurodegenerative processes and AD pathology. However, the exploratory nature of these analyses and the phase 1b design prevent conclusions regarding whether the observed biomarker changes translate into meaningful clinical benefits. The company said the overall safety and tolerability findings support continued clinical development of IBC-Ab002 and its proposed mechanism of transient checkpoint inhibition in AD.¹

Clinical Context

The development of IBC-Ab002 is based on a therapeutic approach that differs from established AD therapies that directly target amyloid plaques or other disease-associated proteins. Rather than attempting to remove a specific pathological protein, the ImmunoBrain approach seeks to modulate the peripheral immune system in an effort to support endogenous mechanisms involved in brain protection and repair.³

The strategy builds on more than 25 years of research led by Schwartz and colleagues examining the relationship between the immune system and the central nervous system.This work has challenged the traditional concept of the brain as an organ that functions independently of peripheral immune activity and has proposed that appropriate immune responses may play a role in maintaining brain health and facilitating repair.

IBC-Ab002 is designed around the hypothesis that transient activation of this pathway may be sufficient to produce therapeutic effects while limiting the potential risks associated with prolonged exposure to checkpoint inhibitors. According to ImmunoBrain, the antibody's short half-life and intermittent dosing schedule are intended to minimize chronic immune exposure.

Limitations and Next Steps

The findings should be interpreted in the context of the phase 1b study design and its primary focus on safety and tolerability. The exploratory biomarker analyses were not designed to establish efficacy, and additional studies will be required to determine whether changes in CSF markers translate into slower cognitive or functional decline in patients with AD.

The company is currently developing the protocol for the next phase of clinical testing. Future trials will be important for determining whether IBC-Ab002 can demonstrate clinical efficacy and whether its proposed mechanism of transient peripheral immune modulation can produce meaningful effects on disease progression.

Together, the phase 1b findings provide early evidence of biological activity and support continued investigation of checkpoint immunotherapy as a potential therapeutic strategy for AD. Larger and longer-term randomized studies will be needed to establish the clinical relevance of the biomarker findings and define the potential role of IBC-Ab002 within the expanding AD treatment landscape.

For more Alzheimer disease coverage, click here!

REFERENCES
1. Croese T, Mummery C, Bergman N, et al.Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer’s disease: a phase 1b, randomized, double-blind trial. Nat. Med. Published: 15 July 2026. 2026;Doi: 10.1038/s41591-026-04547-8
2. ImmunoBrain Announces Nature Medicine Publication and Late-Breaking AAIC 2026 Presentation for IBC-Ab002 in Early Alzheimer's Disease. ImmunoBrain Checkpoint Inc. News Release. July 14, 2026. Accessed: July 27, 2026. https://www.prnewswire.com/il/news-releases/immunobrain-announces-nature-medicine-publication-and-late-breaking-aaic-2026-presentation-for-ibc-ab002-in-early-alzheimers-disease-302825190.html
3.Schwartz M, DeczkowskaA. Neurological disease as a failure of brain-immune crosstalk: a perspective. Nat Immunol. 2016;17(8):882-888. doi:10.1038/ni.3492